COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS’ lead products is macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Company profile
Ticker
CSCI
Exchange
Website
CEO
Klaus Paulini
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AETERNA LABORATORIES INC, Aeterna Zentaris Inc.
SEC CIK
CSCI stock data
Latest filings (excl ownership)
6-K
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
23 Sep 24
6-K
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 Aug 24
6-K
Current report (foreign)
13 Aug 24
6-K
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
13 Aug 24
6-K
Current report (foreign)
6 Aug 24
6-K
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16 Jul 24
20-F/A
2023 FY
Annual report (foreign) (amended)
16 Jul 24
6-K
Current report (foreign)
25 Jun 24
6-K
Company expects to report top-line data and complete study results in Q3 2024
13 Jun 24
424B3
Prospectus supplement
10 Jun 24
Latest ownership filings
SC 13D
Goodwood Inc.
6 Sep 24
SC 13G
Goodwood Inc.
6 Jun 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
Lind Global Macro Fund LP
11 Feb 22
SC 13G/A
ARMISTICE CAPITAL, LLC
16 Feb 21
SC 13G/A
Lind Global Macro Fund LP
12 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G
INTRACOASTAL CAPITAL, LLC
10 Jul 20
SC 13G
Lind Global Macro Fund LP
7 Jul 20
SC 13G
Aeterna Zentaris Inc.
28 Feb 20
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
News
S&P 500 Edges Higher; American Woodmark Shares Slide
27 Aug 24
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
27 Aug 24
US Stocks Mixed; ScanSource Reports Weak Q4 Results
27 Aug 24
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
16 Aug 24
COSCIENS Biopharma Q2 EPS $(0.64) Down From $(0.47) YoY, Sales $2.30M Beat $1.10M Estimate
13 Aug 24
Press releases
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
23 Sep 24
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 Aug 24
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
13 Aug 24
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
6 Aug 24
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16 Jul 24